Patents by Inventor Chris Dockendorff

Chris Dockendorff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10064853
    Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: September 4, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., The Broad Institute, Inc.
    Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz, Chris Dockendorff
  • Patent number: 9951055
    Abstract: This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: April 24, 2018
    Assignees: Massachusetts Institute of Technology, The Broad Institute, Inc.
    Inventors: Chris Dockendorff, Willmen Youngsaye, Partha Pratim Nag, Timothy A. Lewis, Sivaraman Dandapani, Benito Munoz, Patrick Faloon, Thomas Nieland, Monty Krieger, Miao Yu
  • Patent number: 9884851
    Abstract: This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can be used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections. The compounds have the formula: wherein R1 and R2 are independently H, halogen, cyano, haloalkyl, haloalkyloxy or OMe; or R1 and R2 together are —O—CH2— or —O—CF2—O—; R3 is H, halogen, cyano, haloalkyl or haloalkyloxy; R4 is C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylmethyl or C3-6cycloheteroalkyl, wherein the heteroatom is N or O; R5 is H or CH3; R6 is C1-6alkyl or C3-6cycloalkyl; and A, B, D and E are each, independently, CH, N, O or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, O or S.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: February 6, 2018
    Assignees: Massachusetts Institute Of Technology, The Broad Institute, Inc.
    Inventors: Chris Dockendorff, Andrew Germain, Partha Pratim Nag, Willmen Youngsaye, Sivaraman Dandapani, Benito Munoz, Patrick Faloon, Thomas Nieland, Monty Krieger, Miao Yu
  • Publication number: 20170304283
    Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I).
    Type: Application
    Filed: June 26, 2017
    Publication date: October 26, 2017
    Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz, Chris Dockendorff
  • Patent number: 9422262
    Abstract: The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: August 23, 2016
    Assignees: The Broad Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Chris Dockendorff, Robert Flaumenhaft
  • Publication number: 20160060254
    Abstract: This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.
    Type: Application
    Filed: October 21, 2013
    Publication date: March 3, 2016
    Inventors: Chris Dockendorff, Willmen Youngsaye, Partha Pratim Nag, Timothy A. Lewis, Sivaraman Dandapani, Benito Munoz, Patrick Falloon, Thomas Nieland, Monty Krieger, Miao Yu
  • Publication number: 20160046590
    Abstract: Sonic Hedgehog modulators and methods of use thereof are provided for.
    Type: Application
    Filed: March 23, 2015
    Publication date: February 18, 2016
    Inventors: Sara Buhrlage, Chris Dockendorff, Mike Foley, Han-Je Kim, Andrew Germain, Lawrence MacPherson, Partha Pratim Nag, Stuart Schreiber, Amal Ting, Michel Weiwer, Willmen Youngsaye
  • Publication number: 20150284371
    Abstract: This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can be used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections. The compounds have the formula: wherein R1 and R2 are independently H, halogen, cyano, haloalkyl, haloalkyloxy or OMe; or R1 and R2 together are —O—CH2— or -0- CF2—O—; R3 is H, halogen, cyano, haloalkyl or haloalkyloxy; R4 is C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylmethyl or C3-6cycloheteroalkyl, wherein the heteroatom is N or 0; R5 is H or CH3; R6 is C1-6alkyl or C3-6cycloalkyl; and A, B, D and E are each, independently, CH, N, 0 or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, 0 or S.
    Type: Application
    Filed: October 21, 2013
    Publication date: October 8, 2015
    Inventors: Chris Dockendorff, Andrew Germain, Partha Pratim Nag, Willmen Youngsaye, Sivaraman Dandapani, Benito Munoz, Patrick Falloon, Thomas Nieland, Monty Krieger, Miao Yu
  • Publication number: 20140094462
    Abstract: Sonic Hedgehog modulators and methods of use thereof are provided for.
    Type: Application
    Filed: February 28, 2013
    Publication date: April 3, 2014
    Inventors: Sara Buhrlage, Chris Dockendorff, Mike Foley, Han-Je Kim, Andrew Germain, Lawrence MacPherson, Partha Nag, Stuart Schreiber, Amal Ting, Michel Weiwer, Willmen Youngsaye
  • Publication number: 20130331411
    Abstract: The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.
    Type: Application
    Filed: September 23, 2011
    Publication date: December 12, 2013
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, THE BROAD INSTITUTE, INC.
    Inventors: Chris Dockendorff, Robert Flaumenhaft, Lawrence MacPherson